Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.J. Dorer
1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn198 - An Economic Systematic Literature Review (Slr) for Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small-Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer
Lung Cancer: Targets and Therapy
Oncology
174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial
The Lancet Oncology
Oncology
